AR122733A1 - Esteroides neuroactivos y composiciones de estos - Google Patents

Esteroides neuroactivos y composiciones de estos

Info

Publication number
AR122733A1
AR122733A1 ARP210101745A ARP210101745A AR122733A1 AR 122733 A1 AR122733 A1 AR 122733A1 AR P210101745 A ARP210101745 A AR P210101745A AR P210101745 A ARP210101745 A AR P210101745A AR 122733 A1 AR122733 A1 AR 122733A1
Authority
AR
Argentina
Prior art keywords
compositions
neuroactive steroids
compound
formula
neuroactive
Prior art date
Application number
ARP210101745A
Other languages
English (en)
Inventor
Mara Jess Blanco-Pillado
Bingsong Han
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of AR122733A1 publication Critical patent/AR122733A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

En la presente se proporciona un compuesto de la formula (1) o una sal farmacéuticamente aceptable de este, en donde R²ᵃ, R²ᵇ, R⁴ᵃ, R⁴ᵇ, R⁶, R⁷, R¹¹ᵃ, R¹¹ᵇ, R¹⁶, R¹⁷, R³ᵃ, R⁵, R¹⁹, RX y RY se definen en la presente. También se proporcionan en la presente composiciones farmacéuticas que comprenden un compuesto de la fórmula (1) y métodos para usar los compuestos, por ejemplo, en el tratamiento de trastornos relacionados con el SNC.
ARP210101745A 2020-06-24 2021-06-24 Esteroides neuroactivos y composiciones de estos AR122733A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063043641P 2020-06-24 2020-06-24

Publications (1)

Publication Number Publication Date
AR122733A1 true AR122733A1 (es) 2022-10-05

Family

ID=77265178

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101745A AR122733A1 (es) 2020-06-24 2021-06-24 Esteroides neuroactivos y composiciones de estos

Country Status (11)

Country Link
US (1) US20230250129A1 (es)
EP (1) EP4172171A1 (es)
JP (1) JP2023531517A (es)
CN (1) CN115768781A (es)
AR (1) AR122733A1 (es)
AU (1) AU2021296846A1 (es)
CA (1) CA3183248A1 (es)
IL (1) IL299176A (es)
MX (1) MX2022016343A (es)
TW (1) TW202233198A (es)
WO (1) WO2021262836A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
LT3224269T (lt) 2014-11-27 2020-07-10 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti cns sutrikimams gydyti
EP3864022B1 (en) 2018-10-12 2023-09-20 Sage Therapeutics, Inc. Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
CN116162121A (zh) * 2016-07-11 2023-05-26 萨奇治疗股份有限公司 C17、c20和c21取代的神经活性类固醇及其使用方法
AU2018388408B2 (en) 2017-12-22 2023-12-21 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders

Also Published As

Publication number Publication date
WO2021262836A1 (en) 2021-12-30
MX2022016343A (es) 2023-03-06
AU2021296846A1 (en) 2022-12-15
TW202233198A (zh) 2022-09-01
EP4172171A1 (en) 2023-05-03
IL299176A (en) 2023-02-01
CA3183248A1 (en) 2021-12-30
US20230250129A1 (en) 2023-08-10
CN115768781A (zh) 2023-03-07
JP2023531517A (ja) 2023-07-24

Similar Documents

Publication Publication Date Title
AR122733A1 (es) Esteroides neuroactivos y composiciones de estos
AR118707A1 (es) Inhibidores de la proteasa del vih
AR114290A1 (es) Péptidos macrocíclicos contra actinetobacter baumannii
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
ECSP066349A (es) Inhibidores de transferasa de proteína de farnesilo novedosos como agentes antitumorales
CO2022002804A2 (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
CO2024001367A2 (es) Compuestos antivirales
UY37941A (es) Derivados de bencimidazol y sus usos
PE20230182A1 (es) Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter
CL2020001244A1 (es) Inhibidores de inmunoproteasoma.
AR127470A1 (es) Inhibidores de lrrk2
AR128500A1 (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
ECSP034494A (es) Inhibidores novedosos de la farnesil proteino trasferasa como agentes antitumorales
CO2023004649A2 (es) Un inhibidor de magl
CL2022001741A1 (es) Compuestos cíclicos y métodos de uso de estos
ECSP23088732A (es) Moduladores de trex1
AR118141A1 (es) Compuestos para el tratamiento, alivio o prevención de trastornos asociados con los agregados de tau
CO2021017202A2 (es) Compuestos tricíclicos
AR126914A1 (es) Inhibidores de ras novedosos
AR041720A1 (es) Derivados de n- benzodioxolilo, n- benzodioxanilo y n- benzodioxepinilarilcarboxamida que pueden usarse para el tratamiento de dislipidemia, y composiciones farmaceuticas que los contienen
AR126251A1 (es) Inhibidores de cdk2
AR125059A1 (es) Degradadores selectivos del receptor de estrógeno
CL2022001314A1 (es) Fármaco para el tratamiento o la prevención de la hemorragia cerebral, y método para el tratamiento o la prevención de la hemorragia cerebral con dicho fármaco
AR041026A1 (es) Derivados de aril- y heteroarilmorfolina, su uso en la preparacion de un medicamento y composicion farmaceutica